

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

**ANNOUNCEMENT
ALLOTMENT AND ISSUANCE OF DOMESTIC SHARES
UNDER THE 2023 SHARE INCENTIVE SCHEME**

Reference is made to (i) the announcement of the Company dated 29 August 2023, the circular of the Company dated 16 October 2023 (the “**First Circular**”), the announcement of the Company dated 24 November 2023 and the supplemental circular of the Company dated 30 November 2023 (together with the “**First Circular**”, the “**Circulars**”) and (ii) the announcement of the Company dated 19 December 2023 in relation to, among others, the Shareholders’ approval of the proposed adoption of the 2023 Share Incentive Scheme and the proposed grant of Restricted Shares under the 2023 Share Incentive Scheme.

Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circulars.

The Board is pleased to announce that the Company has received approval dated 13 March 2024 from the CSRC (the “**CSRC Approval**”) in relation to the Company’s allotment and issuance of 5,000,000 Domestic Shares under the 2023 Share Incentive Scheme. The CSRC Approval shall be effective for 12 months from 13 March 2024.

The Company will apply to the China Securities and Depository and Clearing Limited for approval of allotting 5,000,000 new Domestic Shares to Dr. Liang Dongke, Mr. Lin Sen, Dr. Song Yuan, Mr. Wang Ruiqin and 13 other employees of the Company (the “**Proposed Allotment**”) in due time within the validity period approved by the CSRC.

Upon completion of the Proposed Allotment, the total number of issued Shares will be 176,000,000, and all the Restricted Shares under the 2023 Share Incentive Scheme will be fully issued.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
15 March 2024

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Mr. Zhang Weixin, Ms. Chen Hongqin, Dr. Song Yuan and Mr. Wang Ruiqin as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*